摘要
研究背景
多囊卵巢综合征(polycystic ovary syndrome, PCOS),是以持续性无排卵、高雄激素或胰岛素抵抗为特征的内分泌紊乱的症候群。卓于1935年Stein和Leventhal首次报道,故又称为Stein-Leventhal综合征。常见临床表现有无排卵型月经失调、不孕、多毛、痤疮、肥胖、黑棘皮症和卵巢多囊性改变等。近年来的研究发现该疾病的功能紊乱远超出生殖轴,由于胰岛素抵抗,常发展为代谢综合征,PCOS代谢综合征的患病率高于正常人群的4-11倍。PCOS不仅对生殖内分泌功能影响,远期可增加代谢综合症、糖尿病、子宫内膜癌及心血管疾病的发病率。近年的研究认为,胰岛素抵抗是PCOS病理生理过程中的中心环节,多数PCOS患者具有胰岛素抵抗。胰岛素抵抗不仅出现在肥胖的PCOS患者中,正常体重的PCOS患者亦有胰岛素抵抗。我院名老中医李丽芸教授根据前人经验结合临床经验提出PCOS中医病机以肾虚痰湿为主,属虚实夹杂之证,研制出灵术颗粒制剂,治疗胰岛素抵抗,临床上取得较好疗效。研究目的
本课题通过动物实验研究,探讨灵术颗粒对PCOS大鼠卵泡基底膜,促进卵泡发育的可能作用靶点,阐明其疗效的可能分子机制,为临床治疗PCOS胰岛素抵抗的基础研究提供实验依据,以期进一步揭示其可能的疗效机理。为中医药治疗PCOS赋予新的内涵,为灵术颗粒临床应用提供科学依据。并通过临床观察研究灵术颗粒与二甲双胍治疗PCOS胰岛素抵抗疗效的对比,研究灵术颗粒治疗PCOS胰岛素抵抗的临床疗效及安全性。
研究方法
本研究本课题通过应用Poresky方法制造PCO大鼠模型。采用随机对照实验的方法,分为灵术颗粒组、二甲双胍组、模型对照组及空白对照组,围绕PCOS卵泡发育及排卵障碍的主要环节,通过观察卵巢形态学、血清T、INS及糖耐量试验、卵泡基底膜厚度和其蛋白表达及颗粒细胞、卵泡内膜细胞数量等的影响等指标,以探讨灵术颗粒可能作用机制。本研究采用临床随机对照研究方法,进行临床疗效评价及安全性评价,将广东省中医院妇科2008年9月-2011年1月在门诊就诊符合纳入标准的患者随机分为治疗组(35例)和对照组(35例),选用灵术颗粒为治疗组,二甲双胍为对照组,采用中医证候评分表,结合女性激素、血脂、血糖及胰岛素、B超等监测。将观察的数据输入SPSS17.0建立数据库并进行统计学分析。
研究结果
1动物实验结果：
(1)空白对照组与造模成功组比较分析：
造模成功组糖耐量、体重、睾酮、胰岛素均数显著高于空白对照组(P<0.05)。
(2)造模成功率分析：Poresky方法造模组大鼠排卵障碍率为80.36%,大鼠死亡率11.67%,但是造模成功率仅有43.33%。
(3)4组治疗后各项指标比较：
4组睾酮、胰岛素均数比较,空白对照组与其余3组分别比较有显著差异(P<0.05),其余组别比较无显著差异(P>0.05)。经药物治疗后,体重均数4组间无显著差异(P=-0.309>0.05)。治疗后,体重均数4组间无显著差异(P＞0.05)。治疗后睾酮、胰岛素均数4组比较,有差异性(P>0.05)。
(4)4组治疗前后差值的比较：
①体重增长值方面,空白对照组与模型对照组比较无显著差异(P=-0.511>0.05),灵术颗粒组与二甲双胍组比较无显著差异(P=-0.905>0.05),其余组别比较均有显著差异性(P<0.05),灵术颗粒组与二甲双胍组体重增长值,明显低于空白对照组与模型对照组,有统计学意义。②睾酮降低幅度方面,空白对照组与模型对照组比较无显著差异(P=-0.962>0.05),灵术颗粒组与二甲双胍组比较无显著差异(P=-1.000>0.05),其余组别比较均有显著差异性(P<0.05),灵术颗粒组与二甲双胍组睾酮下降幅度,均明显高于空白对照组与模型对照组,有统计学意义。③胰岛素降低幅度方面,空白对照组与模型对照组比较无显著差异(P=-0.596>0.05),灵术颗粒组与二甲双胍组比较无显著差异(P=-1.000>-0.05),其余组别比较均有显著差异性(P<0.05),灵术颗粒组与二甲双胍组胰岛素下降幅度,均明显高于空白对照组与模型对照组,有统计学意义。
(5)子宫湿重与总卵巢湿重的比较：
①子宫湿重比较方面,空白对照组与模型对照组比较,可信区间为(-258.0085,-18.3665),可信区间不包括0,表示在α=0.05水准有显著差异性,其他组无显著差异性,但从均数比较,模型对照组(676.68)最高,二甲双胍组(621.01)高于灵术颗粒组(567.87),空白对照组(538.50)最低。②大鼠双侧卵巢总重量比较,表示4组组间均数比较无显著差异,根据均数比较,模型对照组高于二甲双胍组,再次为灵术颗粒组,空白对照组最低。上述数据虽无统计学意义,根据均数比较,有一定临床意义,可见治疗后模型对照组子宫湿重、总卵巢湿重明显高于其他3组,空白对照组最低。由此可见肾虚痰湿型大鼠的子宫及总卵巢湿重明显重于空白组,而二甲双胍组与灵术颗粒组对于降低其重量有一定效果。
(6)大鼠卵泡基底膜3种主要蛋白表达的评级比较：
采用Kruskal-WallisH检验,①Ⅳ型胶原(CollagenⅣ)蛋白表达的4组比较,以模型对照组Ⅳ型胶原表达最多,灵术颗粒组次之,空白对照组再次之,二甲双胍组表达最少。②层连接蛋白(Laminin)蛋白表达的4组比较,以模型对照组Ⅳ型层连接蛋白表达最多,灵术颗粒组与二甲双胍组效果无差异,空白对照组层连接蛋白表达最少。③串珠养蛋白聚糖蛋白(Perlecan)的表达的4组比较有显著差异,以模型对照组串珠养蛋白聚糖表达最多,灵术颗粒组与二甲双胍组效果无差异,空白对照组串珠养蛋白聚糖表达最少。
(7) HitachiH—7500型透射电镜观察卵泡基底膜厚度的比较：
秩和检验,P=O.261>0.05,表示4组组间均数比较无显著差异。但均数比较,模型对照组基底膜厚度(707.52nm)显著高于其他三组,而灵术颗粒组与二甲双胍组基底膜厚度接近空白对照组。
(8)颗粒细胞、卵泡内膜细胞层数的比较：采用Kruskal-Wallis H检验,颗粒细胞与卵泡膜细胞计数4组比较,P>0.05,4组间均无显著差异。
(9) HitachiH-7500型透射电镜观察,空白对照组、灵术颗粒组均有较多黄体细胞,提示大鼠有排卵。
2临床研究结果：
(1)体重指数及腰臀比：
治疗组(灵术颗粒组)与对照组(二甲双胍组)在降低PCOS胰岛素抵抗患者的体重指数及腰臀比均有显著疗效,P＜0.05,提示治疗前后有差异性,有统计学意义。
(2)灵术颗粒与二甲双胍可均显著降低PCOS胰岛素抵抗患者体内胰岛素水平并改善胰岛素抵抗。
经配对t检验,对照组治疗后降低空腹血糖有显著差异,P＜0.05,有统计学意义。治疗组降低餐后2小时血糖、餐后2小时胰岛素及HOMA—β有显著差异,P<0.05,有统计学意义。2组均在降低空腹胰岛素及HOMA-IR有显著差异,P<0.05,有统计学意义。
(3)灵术颗粒组降低TC、升高HDL-C有显著疗效,二甲双胍组降低TG、ApoB有显著疗效。均可降低LDL-C。
配对t检验,治疗组治疗后TC显著低于治疗前(P=0.003<0.05), HDL-C显著高于治疗前(P=0.021<0.05)；对照组TG治疗后显著低于治疗前(P=0.008<0.05),治疗后ApoB显著低于治疗前(P=0.037<0.05)；2组治疗后LDL-C均显著低于治疗前(P<0.05)。2组ApoA/ApoB均无统计学意义。
(4)灵术颗粒与二甲双胍均可降低PCOS胰岛素抵抗患者T水平,二甲双胍降低LH/FSH效果显著。
治疗前后2组女性激素水平的均数比较配对t检验,对照组治疗后LH/FSH水平显著低于治疗前(P=0.025<0.05)；2组治疗后T均显著低于治疗前(P＜0.05),提示治疗前后有显著差异性。在升高E2、降低LH方面,治疗组与对照组治疗前后无显著差异(P>0.05),无统计学意义。
(5)灵术颗粒与二甲双胍在提高BBT双相周期方面无显著差异。卡方检验2组治疗期间BBT双相周期数P=1.563>0.05,2组无显著差异。
(6)在改善中医症候评分方面,灵术颗粒与二甲双胍均有显著效果。
配对t检验,2组治疗后中医症候评分显著低于治疗前(P<0.05)提示2组均能改善PCOS患者中医症候。
(7)本研究的PCOS胰岛素抵抗患者并非全部是肥胖者,非肥胖患者占所有研究对象的43.55%(27/62)；治疗组占51.61%(16/31)；对照组占35.48%(11/31)。
研究结论
本院名老中医李丽芸教授根据前人论述同时结合自己的临床经验提出PCOS中医病机以肾虚痰湿为主,并研究出灵术颗粒剂,全方共奏补肾化痰之功,临床疗效较佳。
本研究表明灵术颗粒治疗肾虚痰湿型PCOS疗效确切,与二甲双胍组比较,PCOS大鼠在体重增长及降低大鼠睾酮、胰岛素方面无差异(P>0.05),2组疗效相似。在降低子宫湿重、总卵巢湿重有一定临床意义。灵术颗粒与二甲双胍均可减少Ⅳ型胶原、层连接蛋白与串珠养蛋白聚糖的表达,对于改善基底膜分子筛方面有着明显作用。在Ⅳ型胶原的表达方面,二甲双胍组优于灵术颗粒组。在层连接蛋白与串珠养蛋白聚糖的表达方面,二甲双胍组与灵术颗粒组无显著差异。灵术颗粒与二甲双胍均可改善基底膜厚度,对于改善基底膜分子筛功能方面有着明显的作用。综上所述,从分子生物学方面,补肾化痰中药灵术颗粒可改善PCOS卵泡基底膜分子筛功能,调节两细胞间信息交换,维持“LH—卵泡内膜细胞轴”和“FSH—颗粒细胞轴”两轴功能平衡,为中医补肾化痰治疗PCOS赋予新的内涵,也为其临床应用提供科学依据。
本研究提示灵术颗粒治疗PCOS胰岛素抵抗疗效显著,与二甲双胍相比较,在治疗该病方面既有相似,又各有所长。降低体重指数、腰臀比,改善胰岛素抵抗方面,二者均有显著疗效。2组在降低空腹胰岛素及HOMA-IR效果无差异,二甲双胍降低空腹血糖较好,灵术颗粒降低餐后2小时血糖、餐后2小时胰岛素及HOMA—β效果较好。灵术颗粒组降低TC、升高HDL-C有显著疗效,二甲双胍组降低TG、ApoB有显著疗效。二者均可降低LDL-C。二者对患者内分泌改善方面,各有千秋,灵术颗粒与二甲双胍均可降低PCOS胰岛素抵抗患者T水平,二甲双胍降低LH/FSH效果显著。降低LH方面,治疗组与对照组治疗前后无显著差异。在改善中医症候评分方面,灵术颗粒与二甲双胍均有显著效果。灵术颗粒与二甲双胍在提高BBT双相周期方面无显著差异。另在确诊PCOS时,不论胖瘦,均应排除胰岛素抵抗,以免遗漏。
Background
Polycystic ovarian syndrome(PCOS) is one of most common endocrine disease, The syndrome encompasses a broader spectrum of signs and symptoms, such as elevated serum hyperandrogenism and insulin resistance. In 1935, Stein and Leventhal reported this disease for the first time, so the disease is named the syndrome of Stein-Leventhal too. PCOS is with different phenotypic aspects, Clinical manifestation of PCOS includes anovulatory menoxenia, infertility, hirsutism, acne, obesity, acanthosis nigricans and PCO. The later-day researches covers that PCOS dysfunction oversteps reproductive axis. Insulin resistance is evolving to metabolic syndromes generally. The probability of PCOS patients suffering from metabolic syndromes is 4-11 times than ordinary persons. Not only it impairs function of procreation and incretion, but also is associated with metabolic syndromes, type 2 diabetes, endometrial carcinoma, cardiovascular and cerebrovascular disease。Latest studies reports that insulin resistance is the physiological and pathological key link of PCOS. Most PCOS sufferers are with insulin resistance. The famous professor Li LiYun of GuangDong Province Hospital Of Traditional Chinese Medicine, according to experiences of the ancients and her clinical experiences, created Ling-Zhu granule for PCOS, especially insulin resistance. It is very availability in the clinic.
Objectives
The aim of this empirical study is to discuss the mechanism target of Ling-Zhu granule ameliorating the follicle basement membrane of PCOS rat, and accelerate the development of the follicle, to illuminate the molecular mechanism of the effect. It could be provide evidences for the clinical treatment and new contents of Traditional Chinese Medicine. The aim of this clinical study is to discuss the clinical curative effect and security of Ling-Zhu granule. The research is according to the comparison of Ling-Zhu granule and Metformin in treatment of patients with polycystic ovary syndrome and insulin resistance.
Methods
This study is basis of Poresky Methods to make the formers of PCO rats. The rats were divided into four groups by randomization and comparison, study group, control group, former group and blank group. This study is to discuss the main mechanism of the development of the follicle and the ovulation failure, to discuss the possible mechanism of Ling-Zhu granule, by observing the targets, such as ovarian configuration, T, insulin, OGTT, the thickness of the follicle basement membrane, the expression of the protein of the follicle basement membrane, the quantity of granular cells and theca cells. According to the RCT and the diagnosis criterion, The clinical study collected 70 patients of from Province Hospital Of Traditional Chinese Medicine, from 2008.9-2011.1 They are divided into two groups by 1:1 randomly, Ling-Zhu granule is given to treatment group including 35 cases, and at the same time Metformin is given to the control group also including 35 cases, two groups are inspected by using Chinese medicine syndromes graded tables and other observe variable index, such as female hormone, blood-fat, blood glucose, insulin, type-B ultrasonic. Lastly, the study data collected to make the data-base is analyzed by the software of SPSS17.0.
Results
1 Results of empirical study
(1)The comparison of the blank group and the succeeded animal model group:
The latter surpass the former in these mean observe index, such as OGTT, avoirdupois, T, insulin.
(2)The analysis of the animal model succeeded: The rats of ovulation failure account for 80.36%, the dead rats account for 11.67%, and the rats succeeded account for 43.33%.
(3)The comparison of the four groups indexes:
To the mean of T and insulin, the blank group is distinct statistical differences between the other groups (P<0.05). There is no distinct statistical differences between the others (P>0.05). After the therapy, There is no distinct statistical differences between the four groups of the mean of weight (P>0.05). There is distinct statistical differences between the four groups the mean of insulin and T (P<0.05)
(4)The difference of the four groups After the therapy:
①weight:There is no distinct statistical differences between the blank group and the former group (P=0.511>0.05), the study group and the control group (P=0.905>0.05), except between other groups (P<0.05). The increase of weight of the study group and the control group is under the others, it has the statistical significance.②T:There is no distinct statistical differences between the blank group and the former group (P=0.962>0.05), the study group and the control group (P=1.000>0.05), except between other groups (P<0.05). The decrease of T of the study group and the control group is under the others, it exists the statistical significance.
(5)The comparison of the green weight of uteruses and ovaries:
①the green weight of uteruses:the comparison of the blank group and the former group:confidence interval (CI) (-258.0085,-18.3665), except 0, a =0.05, There is distinct statistical differences, there is no distinct statistical differences between other groups. But from The comparison of the mean, the first is the former group, the second is the control group, the third is the study group, the last is the blank group.②the green weight of ovaries: There are no distinct statistical differences between the four groups. But from The comparison of the mean, the first is the former group, the second is the study group, the third is the control group, the last is the blank group. Although it does not exist statistical significance to the data, it exist clinical significance. After the therapy, the green weight of uteruses and ovaries of the former group are more overweight than the others. The last is the blank group. So the green weight of uteruses and ovaries of the rats of "deficiency of kidney with sputum", are distinct overweight than the blank rats. The Ling-Zhu granule and Metformin are effective to lose weight.
(6)The comparison of the three proteins of the follicle basement membrane of PCOS rat:
With Kruskal-Wallis H method;①CollagenⅣ:the former group is the most of the expression of CollagenⅣ, the second is the study group, the third is the blank group, the last is the control group.②Laminin:The former group is the most of the expression of Laminin, the second is the study group and the control group, the last is the blank group.③Perlecan:There are distinct differences between the four groups. The former group is the most of the expression of Perlecan, the second is the study group and the control group, the last is the blank group.
(7)The mean thickness of the follicle basement membrane:
There is no distinct statistical differences between the four groups (P=0.261>0.05). The former group is the most thickness of the follicle basement membrane (707.52nm), the study and the control groups are close to the blank group.
(8)The quantity of granular cells and theca cells:
With Kruskal—Wallis H method; there is no distinct statistical difference between the four groups (P>0.05).
(9)Ransmission electron microscope (HitachiH-7500):
There are many yellow bodies of the blank and the study groups. It shows ovulation.
2 Results of Empirical study
(1)BMI、WHR:
There is distinct statistical difference between the study group and the control group (P<0.05).
(2) Ling-Zhu granule and Metformin can reduce insulin and insulin resistance of the patient of PCOS and insulin resistance.
Paired t-test, In fasting blood-glucose, there is distinct statistical difference in the control group (P<0.05), there is statistical significance too. In reducing 2-hour postprandial blood glucose,2-hour postprandial insulin and HOMA—β, the study group has distinct statistical difference (P <0.05) and statistical significance. In reducing fasting insulin and HOMA-IR, they both have distinct statistical difference (P<0.05) and statistical significance.
(3)Ling-Zhu granule can reduce TC and increase IIDL-C, Metformin can reduce TG、ApoB. They both can reduce LDL-C.
Paired t-test, in reducing TC (P=0.003<0.05), increasing HDL-C (P =0.021＜0.05), there is distinct statistical difference in the study group than before. In reducing TG (P=0.008<0.05) and ApoB (P=0.037<0.05), there is distinct statistical difference in the study group than before. In reducing LDL-C, there is distinct statistical difference in the both groups than before (P<0.05).There is no distinct statistical difference in the both groups to ApoA/ApoB.
(4)Ling-Zhu granule and Metformin can reduce free testosterone. Metformin can reduce LH/FSH.
In reducing LH/FSH, there is distinct statistical difference in the control group than before (P=0.025<0.05).In reducing free testosterone, there is distinct statistical difference in the both groups than before (P <0.05).In reducing LH and increasing E2, there is no distinct statistical difference in the both groups (P>0.05)
(5)There is no distinct statistical difference in the both groups in basal body temperature (BBT) with two-phase.
Chi-square test, in the BBT with two-phase during the treatment, there is no distinct statistical differences between the two groups (P=1.563> 0.05).
(6)Paired t-test, the point of Chinese medicine syndromes graded tables decline in the two groups is no distinct statistical difference (P<0.05). Fat and not-fat:
(7)The patient of PCOS and insulin resistance in this study are not all fat.
The not-fat patient account for 43.55%(27/62),the study group 51.61% (16/31);the control group 35.48%(11/31)
Conclusion
The famous professor Li LiYun of GuangDong Province Hospital of Traditional Chinese Medicine, according to experiences of the ancients and her clinical experiences, declared that "deficiency of kidney with sputum" is the pathogenesis of PCOS, and created Ling-Zhu granule of restoring kidney and eliminating sputum for PCOS. Ling-Zhu granule is very availability in the clinic.
This study shows that Ling-Zhu granule is effective to treatment the patient of PCOS of "deficiency of kidney with sputum". Compare to Metformin, there is (P>0.05) in the changes of the weight, free testosterone and insulin of rats. In reducing the green weight of uteruses and ovaries, Metformin is more effective than Ling-Zhu granule. There is clinical significance to the both groups. The both medi distinct statistical differences between the two groups caments are effective to reduce the expression of the three proteins, and to ameliorate the molecular sieve of the follicle basement membrane of PCOS rat. The Metformin is more effective to reduce the expression of the Collagen IV than the study group. There is no distinct statistical difference between the both medicaments in reducing the expression of Laminin and Perlecan. The both medicaments can ameliorate the thickness of the follicle basement membrane, so to ameliorate the molecular sieve of the follicle basement membrane of PCOS rat.
In molecular biology, Insulin resistance of restoring kidney and eliminating sputum, can ameliorate the membrane molecular sieve of the follicle basement membrane, accommodate the communication of the two cells, and maintain the balance the function of "LH-theca cells axes and FSH-granular cell axes". It gives new content to the restoring kidney and eliminating sputum of Chinese Medicine, and provides the scientific evidence of the clinical application.
This study shows that Ling-Zhu granule is very effective to treat the patient of PCOS and insulin resistance. Compare to Metformin, they are both effective, but have some dissimilarity. In reducing BMI、WHR and Insulin resistance, they both effective. There are no distinct statistical differences between the two groups in reducing fasting insulin and HOMA-IR. In reducing fasting blood glucose, Metformin is more effective. In reducing 2-hour postprandial blood glucose,2-hour postprandial insulin and HOMA—β, Ling-Zhu granule is more effective. Ling-Zhu granule is effective in reducing TC and increasing HDL-C. Metformin is effective in reducing TG and ApoB. They are both effective to reduce LDL-C. They are both effective to incretion, but have some dissimilarity. Ling-Zhu granule is more effective to reduce LH. They both can reduce free testosterone. The point of Chinese medicine syndromes graded tables decline in the two groups is no distinct statistical difference. There is no distinct statistical difference in the both groups in basal body temperature (BBT) with two-phase. A patient is diagnosed, without reference to fat or not, insulin resistance is needed to diagnose.
引文
[1]Lakhani K,Seifalian AM, et al. Br J Radiol,2002 Jan; 75(889):9-16
[2]钟茜,多囊卵巢综合征的诊断与治疗进展.华西医学,2006；21(1)：186-188
[3]Azziz R, Marin C, Hoq L, Badamgarav E, Song P. Health care-related economic burden of the polycystic ovary syndrome during thereproductive life span. J Clin Endocrinol Metab.2005,90 (8):4650-8.
[4]刘广南,邝少松,潘竞锵等.益肾Ⅰ方对PCOS大鼠胰岛素抵抗及血糖、血脂的影响.中医药临床杂志,2009；21(3)：189-191
[5]王兴娟戴婷等,肾虚型多囊卵巢综合征与血清T、LH的相关性研究.上海中医药杂志,2006；40(8)：40-43
[6]李卫平,沈飞霞,朱虹,高胰岛素一正葡萄糖钳夹术评估多囊卵巢综合征患者胰岛素敏感性的研究—附67例分析.新医学,2009；40(4)：246-248
[7]黄礼云,补肾化瘀汤辅助治疗多囊卵巢综合征40例.中国中西医结合杂志,2008；28(3)：277-278
[8]林金芳.多囊卵巢综合征病理生理及助孕策略.全国女性生殖内分泌及不育诊治进展学习班论文汇编,2009；61
[9]林秀英,冯丽华,多囊卵巢综合征病因学研究进展.吉林医学,2008；6 29(12)：973-975)。王凌宇
[10]王凌宇,匡洪影,李威等.以丝氨酸磷酸化假说阐述PCOS的发病机制.医学研究杂志,2009；38(7)：111-113
[11]丰有吉,沈铿,妇产科学.北京,2006；人民卫生出版社,252
[12]Dunaif A, Thomas A. Current concepts in the polycystic ovary syndrome [J]. Ann Rev Med,2004, (52) 401
[13]Dunalf A. Insulin resistance and the polycystic ovary syndrome:mechanism and implications for pathogenesis[J]. Endocr Rev,2004, (18) 774
[14]丁波,石玉华,亚力,多囊卵巢综合征基因学研究进展.山东医药,2008；48(11)：105-107
[15]Sepilian VP, Crochet JR, Nagamani M. Serum soluble leptin receptor levels and free leptin index in wom en with polycysticovary syndrome:relationship to insulin resistance and andro-gens[J]. Fertil Steril,2006; 85:1441-1447
[16]Puder JJ, Varga S, Kraenzlin M, et al. Central fat excess in polycystic ovary syndrome:relation to low— grade inflamm ation and insulin resistance[J]. J Clin Endocrinol Metab,2005; 90:6014-6021
[17]张琴芬,韩素萍,崔毓桂等.胰岛素基因可变重复序列多态性与PCOS的相关性.国 际生殖健康/计划生育杂志,2010；29(4)：252—255
[18]胡振兴,乔杰,李美芝等.多囊卵巢综合征相关基因的差异表达研究[J].北京大学学报(医学版),2004；36：600—604
[19]张丽珠,临床生殖内分泌与不育症.北京：科学出版社,2001；367
[20]吕海燕,多囊卵巢综合征与高雄激素血症,中国中医药咨讯,2010年；2(9)：193
[21]El Mkadem SA, Lautier C, Macari F. Role of alelic variants Gly972Arg of IRS——1 and Gly1057Asp of IRS-2 in mod erate-to-severe insulin resistance of women with polycystic ovary syndrome[J]. Diabetes,2006,50(9):2164
[22]林秀峰,吴日然,杜静,游离睾酮指数对诊断多囊卵巢综合征高雄激素血症不孕患者的价值.中山大学学报(医学科学版),2010；31(3)：391—396
[23]Balen AH, Conway GS, Dieguez C. The role of leptinin reproduction: experimental and clinical aspects[J]. Ann Med,2002,340:5;
[24]Shell ing AM, Buon KA, Chand AL. Inhibin:A candidate gene for premat~e ovarian failure[J]. Hum Reprod,2006,15:2644
[25]高献青,孙宝治,肥胖型与非肥胖型多囊卵巢综合征的特征及其治疗.齐鲁医学杂志,2005；20(2)：103
[26]夏燕,郑建淮,多囊卵巢综合征可能为慢性炎症性疾病.中国妇幼健康研究.2008；19(2)：160-161
[27]Kuseu NK, Koyuneu F, Ozbilgin K. Insulin:does it induce follicular arrest in the rat ovary[J]. Gynecol Endocrinol,2006,16(5):361
[28]王凌宇,匡洪影,李威等.以丝氨酸磷酸化假说阐述PCOS的发病机制.医学研究杂志,2009；38(7)：111-113
[29]Hotamisligil GS, Arner P, Atkinson RL, et al. Differential regulation of the P80 TNF receptor in human obesity and insulin resistance. Diabetes,1997; 46:451-155
[30]Gonzalez F, Thusu K, Abdel—Rahman E, et, al. Elevated serum levels of Tumor Necrosis Factor Alpha in blank weight with polycystic ovary syndrome. Metabolism,1999; 48:437-441
[31]胡静,杨菁,徐望明等.TGF—β、TNF—α、IL—6与多囊卵巢综合征发病关系的探讨.实用医学杂志,2004；20(11)：1237-1239
[32]徐雯,抑制素、胰岛素样生长因子—Ⅰ与多囊卵巢综合征.国外计划生育分册,2004；23(1)：40—43
[33]丁鸿燕,杨丽红,王兵勇,类胰岛素样生长因子—1和抑制素与多囊卵巢综合征相关性分析.江西医学检验,2006；24(3)：211—213
[34]赵波,邵明君,陈黎,瘦素与多囊卵巢综合征的相关研究.浙江临床医学,2007；9(7)：889-890
[35]张展,贾莉婷,王雪梅,EGF和TGF—α对多囊卵巢综合征患者颗粒细胞分泌E2的影响.郑州大学学报(医学版),2006；41(3)：478—490
[36]罗晓燕,王蕊,抗苗勒管激素与多囊卵巢综合征.国际生殖健康/计划生育杂志,2010；29(2)：105-108
[37]hyperinsulinism in polycystic ovarian disease[J]. J Clin Endocrin Metab, 1980.50(1):113
[38]夏燕,郑建淮,多囊卵巢综合征可能为慢性炎症性疾病.中国妇幼健康研究,2008；19(2)：160—161
[39]丁波,石玉华,亚力,多囊卵巢综合征基因学研究进展.山东医药,2008；48(11)：105—107
[40]张娟辉,孔欣,李琴,四种方法治疗难治性PCOS疗效对比观察.山东医药,2009；49(34)：77—79
[41]李可君,韩玉嵬,张慧英等.多囊卵巢综合征患者胰岛素抵抗的临床分析.现代妇产科进展,2008；7(17)：573—574
[42]王竹晨,顾熊飞,杨冬梓等.脂肪组织中胰岛素受体底物蛋白的表达及酪氨酸磷酸化在多囊卵巢综合征发病中的作用[J].中华妇产科杂志,2005；40：120—123
[43]邱红玉,初永丽,李曼等.多囊卵巢综合征合并胰岛素抵抗患者脂肪组织胰岛素受体底物2蛋白的表达及酪氨酸磷酸化的研究[J].中华妇产科杂志,2005；40：116
[44]王佳宁,阮祥燕,多囊卵巢综合征患者健康相关生活质量的研究.实用妇产科杂志,2007：23(10)：610—614
[45]陈敏章,中华内科学[M],第1版,北京：人民卫生出版社,1999；3209
[46]Matthews DR, HOSker JP. Rudenski AS. et al. Homeostasis model assessm ent: insulin resistance and beta cell function from fasting plasma glucose and insulin concentrations in man [J]. Diabetologia,1985,28:412-419.
[47]李光伟,胰岛素抵抗评估及胰岛素缺乏对其影响[J].糖尿病学新动态,2001；11(6)：1-6
[48]王全胜,刘树琴,杨明功等.稳态模型和最小模型在胰岛素抵抗中的应用.疾病控制杂志,2003；7(6)：539-541
[49]袁慧娟,汪艳芳,马书平等.多囊卵巢综合征胰岛素抵抗特征及相关因分析[J].临床心身疾病杂志,2006；12：4—6
[50]贾伟平,项坤三,陆俊茜等.中国人糖耐量异常与胰岛素抵抗和胰岛素分泌.中国糖尿病杂志,2000；8：67-71
[51]杨冬梓,陈晓莉,PCOS胰岛素抵抗的检测和评估.实用妇产科杂志,2005,21(9)： 515-518
[52]林金芳,李昕,朱铭伟,多囊卵巢综合征的分型探讨.中华妇产科杂志,2006；41(10)：648—652
[53]丰有吉,沈铿,妇产科学.北京,2006；人民卫生出版社,254—255
[54]田亚琴,王勇,多囊卵巢综合征的预防及治疗研究进展.中华妇幼临床医学杂志(电子版),2009；5(1)：67-70
[55]王晓红,韩美英.达英—35治疗多囊卵巢综合征的临床效果观察.中国计划生育学杂志.2007；8(142)：490
[56]陆湘,汪玉宝,张炜,达英-35对非肥胖、非胰岛素抵抗多囊卵巢综合征胰岛素敏感性的影响.实用妇产科杂志,2004；20(6)：340
[57]翟晓华,黄晓兰,复方醋酸环丙孕酮联合安体舒通治疗PCOS不孕的疗效观察.实用妇产科杂志,2007；23(8)：492—494
[58]穆兰芳,扬欣,肥胖为特征的青春期多囊巢综合征21例分析.青海医药杂志,2007；37(3)：27—28
[59]李武呜,谢铁男,多囊卵巢综合征组织胰岛素抵抗及治疗的研究进展.吉林医学,2010；31(4)：534—535
[60]Seli E, Duleba AJ. Should patients with polycystic ovarian syndrome be treated with metformin? Hum Reprod,2002; 17:2230
[61]Valazquez E, Acosta A, Mendoza SG. Menstrual cyclicity after metformin therapy in polycystic ovary syndrome. Obstrc Gynecol,1997; 90:392
[62]Morite Papunen LC, Koivumen RM, Ruokonen A, et al. Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome. Fertil Steril,1998; 69:691
[63]罗婷,韩阳,刘义,二甲双胍治疗多囊卵巢综合征合并胰岛素抵抗对改善内分泌、代谢及排卵功能的疗效观察.中国误诊学杂志,2008； 8(8)1775—1777
[64]Lord JM, Flight IH, Norman RJ. Metformin in polycystic ovary syndrome: systematic review and meta analysis. BMJ,2003; 327:951
[65]滕悦秋,郑建华,韩向阳,二甲双胍治疗多囊卵巢综合征的临床效果评价.哈尔滨医科大学学报,2007；4：405
[66]张翠莲,高航云,赵志刚等.罗格列酮和二甲双胍治疗胰岛素抵抗.多囊卵巢综合征的临床研究[J].中国实用妇产科杂志,2004；20(8)：477
[67]王小萍,胡丽莎,罗格列酮与二甲双胍联用治疗多囊卵巢综合征胰岛素抵抗.实用中西医结合临床,2005；5(5)：52—53
[68]史樱,金婧,达英—35联合二甲双胍治疗多囊卵巢综合征的疗效观察.中国妇幼保健,2007；24：3449—3450
[69]陈志文,冯韵琴,张苗,二甲双胍联合达英—35治疗多囊卵巢综合征临床疗效观察.实用预防医学,2007；14(4)：1165—1166
[70]任建民,吕怡静,唐宽晓等.罗格列酮联合二甲双胍治疗多囊卵巢综合征的临床疗效观察[J].现代妇产科进展,2004；13(3)：197—199.
[71]姜荣华,徐望明,杨菁,达英—35联合罗格列酮对多囊卵巢综合征胰岛素抵抗患者的临床疗效.生殖医学杂志,2005；14(2)：108—110
[72]易艳萍,周春慧,李明,二甲双胍联合克罗米芬改善多囊卵巢综合征患者排卵效果的临床观察.医学临床研究,2007；24(6)：1003—1005
[73]Meridis E, Lavery S. Drugs in reproductive medicine[J]. Curt Obstet Gynaecol, 2006; 16:281—288
[74]AL—Inany H, AboulgharM. GnRH antagonist in assisted reproduction:a Cechrane review[J]. Hum Reprod,2002; 17(4):874—875
[75]Holzer H, Casper R, Tulandi T. A new era in ovulation induction [J]. Fertll Steril,2006; 85(2):277—284
[76]林琳,王智文,金海红,来曲唑对难治性PCOS患者的促排卵效果观察.山东医药,2007：47(6)：73—74
[77]陈孟君,胡燕燕,来曲唑与枸橼酸氯米芬对多囊卵巢综合征患者促排卵疗效分析.现代实用医学,2010；22(3)：315—317
[78]余晓,俎德学,叶玲荣,腹腔镜下卵巢楔形切除术治疗难治性多囊卵巢综合征疗效分析.江西医药,2008；43(2)：148—150
[79]杨红文,黄永芳,陈忠东,腹腔镜治疗多囊卵巢综合征临床疗效评价.生物医学工程与临床,2007；11(3)：200—203
[80]曹华斌,向允媛,吴荣珍,腹腔镜卵巢打孔对PCOS耐氯米芬患者的疗效研究.实用妇产科杂志,2007；23(3)：157—161
[81]LindAK, Weijdegard B, Dahm-Kahler P, et al. Collagens in the human ovary andtheir changes in the perifollicular stroma during ovulation. Acta Obstet Gynecol Scand.2006; 85(12):1476-84
[82]RODGERS R J, IRVING—RODGERS H F, RUSSELL D L. Extracellular matrix of the developing ovarian follicle[J]. Reproduction,2003; 126(4):415—424
[83]武秀峰,IGF—I对卵泡内膜细胞增殖及其LH受体表达的影响.生殖与避孕,2002；22(2)：84-86
[84]冯淑英,PCOS患者卵泡基底膜蛋白的免疫组化研究。中山大学学报(医学科学版),2006：27(2)：161-164
[85]RAPTIS A E, VIBERTI G. Pathogenesis of diabetic nephropathy [J]. Exp Clin Endocrinol Diabetes,2001,109, suppl 2:S424-437
[86]YEN SSC, JAFFE R B, BARBIERI RL. Reproductive Endocrinology (physiolog, pathophysiologyand clinical management) [M].4th ed. Hareout Asia W. B. Saunders, 2001:436—495
[87]RODGERS R J, IRVING—RODGERS H F, RUSSELL D L. Extracellular matrix of the developing ovarian follicle[J]. Reproduction,2003,126(4):415—424
[88]冯淑英,邝健全,多囊卵巢综合征患者卵泡基底膜超微结构的研究[J].电子显微学报,2005；24(2)：133-136
[89]高磊,李威,吴效科等.卵泡膜细胞的胰岛素抵抗对其雄激素合成的影响以及胰岛素增敏剂的调控机制.科技导报,2008；26(19)：78—84
[90]Zeleznik AJ. The physiology of follicle selection. Reprod Biol Endocrinol, 2004,12(2):31-9
[91]龚衍,李尚为,樊伟,胰岛素对卵巢颗粒细胞的作用.生殖与避孕,2008；28(11)：677—680
[92]Jakimiuk AJ, Weitsman SR, Navab A, et al. Luteinizinghormone receptor, steroidogenesis acute regulatory protein, and steroidogenic enzyme messenger ribonucleic acids areoverproduced in thecal and granulosa cells from olycystic
ovaries. J Clin Endocrinol Metab,2001,86(3):18-23
[93]刘艳丽,PCOS大鼠模型的研究现状.河南医学研究,2010；19(1)：114—118
[94]胡颜霞,张展,来曲唑诱导多囊卵巢综合征大鼠模型的研究.中国妇幼保健,2006；21：957-959
[95]程泾,李淑娟,多囊卵巢综合征动物模型构建的研究进展与评价,浙江中西医结合杂志,2009年,19(7)：454-455
[96]孙晓峰、游卉,尤昭玲教授治疗多囊卵巢综合征经验介绍.新中医,2007；39(2)：10-11.
[97]孙斐,俞瑾,张利能等.中药天癸方对雄激素致不孕大鼠下丘脑Leptin受体及神经肽YmRNA的影响.中国中西医结合杂志,2000；20(5)：362
[98]侯璟汶,俞瑾,魏美娟,中药天癸方治疗多囊卵巢治疗综合征中高雄激素高胰岛素血症的研究.中国中西医结合杂志,2000；20(8)：589
[99]田萍,朱三平,启宫丸加减治疗多囊卵巢综合征30例[J].河南中医,1999；19(3)：44
[100]付灵梅,马红霞,尤昭玲教授论治多囊卵巢综合征的经验[J].中医药学刊,2003；21(9)：1481
[101]夏阳,苍附导痰汤加减治疗肥胖型多囊卵巢综合症30例[J].天津中医药,2004；21(2)：169
[102]伍娟娟,李克湘,从补肾活血法论治多囊卵巢综合征之探讨.中医药导报,2006； 12(9)：9-11
[103]蔡平平,补肾活血调经汤治疗肾虚血瘀型多囊卵巢综合症的临床研究[D].山东中医药大学2003届硕士学位论文集,2003；16
[104]夏阳,苍附导痰汤加减治疗肥胖型多囊卵巢综合征30例.天津中医药,2004；21(2)：169-170
[105]许金榜,林莺,健脾益肾活血法改善多囊卵巢综合征胰岛素抵抗理论探讨；福建中医学院学报,2005；15(2)：50-52
[106]马静,金季玲,补肾化痰法治疗肥胖型多囊卵巢综合征30例.山东中医杂志,2007；26(8)：537-538
[107]何贵翔,沙玲,补肾滋阴汤对PCOS患者月经周期及性激素影响的临床观察.华西医学,2009；(7)：1-4
[108]刘广南,邝少松,潘竞锵等.益肾Ⅰ方对PCOS大鼠胰岛素抵抗及血糖、血脂的影响.中医药临床杂志,2009；21(3)：189-191
[109]王燕萍,顺慧芳,补肾化痰活血法治疗青春期多囊卵巢综合征33例临床观察.2008；15(2)：66-67
[110]刘霞,张春霞,卓毅,卓毅教授诊治多囊卵巢综合征临床经验总结.现代中西医结合杂志,2010；19(9)：1102—1103
[111]黄礼云,补肾化瘀汤辅助治疗多囊卵巢综合征40例.中国中西医结合杂志,2008；28(3)：277-278
[112]申霞,补肾活血颗粒治疗多囊卵巢综合征中高雄激素血症92例.中原医刊,2006；33(22)：50
[113]王旭芳,自拟补肾疏肝汤治疗多囊卵巢综合征36例临床观察.社区中医药,2008；10(178)：81
[114]卢丽为,李丽华,补肾疏肝活血汤治疗多囊卵巢综合征15例.现代中西医结合杂志,2006：15(2)：218
[115]陈小平,谢波,郑洁莉等.补肾疏肝汤对肾虚肝郁型多囊卵巢综合征患者临床症状及性激素的影响.中国中医药信息杂志,2008；15(5)：17-20
[116]桑霞,龙胆泻肝汤加减治疗肝经郁火型多囊卵巢综合征25例.新中医,2007；39(10)：62-63
[117]刘丽清,刘雁,曹娟,中医对多囊卵巢综合征的认识及证治体会.中西医结合研究,2010：2(1)：52—54
[118]郝兰枝,魏俊英,中药人工周期治疗青春期多囊卵巢综合征40例,中医研究,2003年,16(3)：35-36
[119]杨悦娅,朱南孙治疗多秦卵巢综合征的思路与方法.上海中医药杂志,2006；40(1)：43-44.
[120]郑姜钦,吕绍光,李红,中药人工周期治疗多囊卵巢综合征45例.中医药杂志,2008：23(5)：458-460
[121]王晓燕,张玉洁,昊富东,针刺治疗多囊卵巢综合征26例.上海针灸,2007；26(7)：28
[122]胡智海,王毅,沈鸿斌,针刺“气海”与“三阴交”对胰岛素抵抗型多囊卵巢综合征内分泌调整作用的对比研究.针灸临床杂志,2009；25(4)：1-2
[123]王珍萍,补肾化痰法加针灸治疗多囊卵巢综合征25例[J].湖北中医杂志,2007；29(6)：31
[124]黄敏,赖红,吕凤冰等.中西按灸疗法治疗多囊卵巢综合征.按摩与导引,2007；23(1)：5—6
[125]王彤,丛惠芳,补肾活血药配合电针治疗多囊卵巢综合征不孕症临床观察38例.中华医学研究杂志,2006；5(6)：676—677
[126]陈栋,邓列华,陈恕仁等.针挑治疗多囊卵巢综合征临床观察.中国针灸,2007；27(2)：99-102
[127]王文靖,高天畅,针灸在多囊卵巢综合征患者宫腔内人工授精助孕术中的应用.中国组织工程研究与临床康,2007：11(39)：7996-7997
[128]侣雪平,丛惠芳,王晓滨,针药并用治疗多囊卵巢综合征排卵障碍的疗效观察.针灸临床观察,2007；23(8)：35-36
[129]王晓冰,侯丽辉,吴效科,痰浊与多囊卵巢综合征胰岛素抵抗的关系研究.中国中医基础医学杂志,2008；14(2)：122-124
[130]刘娟,卢君,梁瑞宁,多囊卵巢综合征伴胰岛素抵抗中医证候研究.国际中医中药杂志,2007；29(5)：272-275
[131]熊红萍,李灿东,多囊卵巢综合征痰证病理与胰岛素抵抗、性激素关系的研究.现代中西医结合杂志,2009；18(1)：13-15
[132]邓春枝,骆黎静,刘新蕊,补肾方治疗肾阴虚型多囊卵巢综合征临床观察.2007；25(9)：1985-1986
[133]吴建辉,俞超芹,周巧玲等.补肾化瘀祛痰方治疗多囊卵巢综合征的临床研究.中国中西医结合杂志,2007：27(10)883-886
[134]许金榜,吕绍光,林元等.中医药治疗多囊卵巢综合征胰岛素抵抗30例临床观察.福建医药杂志,2007；29(5)：145-148
[135]周静,高晟,吴深涛,化浊解毒法治疗多囊卵巢综合征合并胰岛素抵抗27例.天津医药,2009；37(9)：782—783
[136]王兴娟 戴婷,肾虚型多囊卵巢综合征与血清T、LH的相关性研究.上海中医药杂志,2006：40(8)：40-43
[137]曹泽毅,中华妇产科学[M],北京：人民卫生出版社,1999；2188-2202
[138]刘晴,施建蓉,从二仙汤拆方对大鼠卵泡颗粒细胞分泌功能的影响探讨方剂组成原理.中国药学杂志,2005；40(21)：1623-1625
[139]沈嵘,夏天,韩冰等.补肾调冲方含药血清对高雄激素培养的卵巢颗粒细胞IGF—1, StAR mRNA表达的影响,辽宁中医杂志,2006；33(6)：748-750
[140]夏天,付于,补肾调冲方含药血清对高雄激素培养大鼠卵巢颗粒细胞增殖与分泌的影响.中国中西医结合杂志,2006；26(4)：348-350
[141]张梅,宋芹,郭平,仙茅对去势小鼠补肾壮阳作用有效成分研究,四川中医,2006年,24(2)：22-23
[142]夏天,付于,补肾调冲方含药血清对大鼠卵巢颗粒细胞增殖与分泌及其FSHR mRNA表达的影响.中药药理与临床,2006；22(2)：54-56
[143]徐珉,司徒仪等,中医补肾法对高龄不孕妇女的卵巢储备功能的调控,广州中医药大学学报,2004,21(4)267-270
[144]黎小斌,李丽芸,导痰种子方联合克罗米芬治疗多囊卵巢综合征,实用医学杂志,2000,16(4)：330-332
[145]黎小斌,李丽芸等,腹腔镜手术辅以补肾化痰中药治疗多囊卵巢综合征,中药新药与临床药理,2002,13(2)
[146]胡向丹,黄旭晖,灵术冲剂联合参芪胶囊治疗多囊卵巢综合征34例.实用医学杂志,2007,23(18)：2950—2951
[147]黄继汉,黄晓晖,陈志扬等.药理试验中动物间和动物与人体间的等效剂量换算.中国临床药理学与治疗学,2004；1069-1972
[148]林金芳,李昕,朱铭伟,多囊卵巢综合征的分型探讨.中华妇产科杂志,2006；41(10)：648—652
[149]郑筱萸,新药中药临床研究指导原则.中国医药科技出版社,北京,2002；239—232；385—387
[150]田萍,朱三平,启丸加减治疗多囊卵巢综合征30例[J].河南中医,1999；19(3)：44
[151]付灵梅,马红霞,尤昭玲教授论治多囊卵巢综合征的经验[J].中医药学刊,2003；21(9)：1481
[152]熊红萍,李灿东,多囊卵巢综合征痰证病理与胰岛素抵抗、性激素关系的研究.现代中西医结合杂志,2009；18(1)：13-15
[153]林金芳,多囊卵巢综合征病理生理及助孕策略.全国女性生殖内分泌及不育诊治进展学习班论文汇编,2009；61
[154]YEN SSC, JAFFE R B, BARBIERI RL. Reproductive Endocrinology (physiolog, pathophysiologyand clinical management) [M].4th ed. Hareout Asia W. B. Saunders, 2001:436—495
[155]梁莉,乔华,王婷,盐酸二甲双胍的不良反应.中国药事,2007；21(8)：652-654
[156]周丽荣,俞瑾.补肾阴药治疗高胰岛索高雄激素无排卵临床观察[J],中国中西医结合杂志,1996,16(9)：515-518
[157]夏阳,苍附导痰汤加减治疗肥胖型多囊卵巢综合征30例,天津中医药,2004,21(2)：169-170
[158]许金榜,林莺,健脾益肾活血法改善多囊卵巢综合征胰岛素抵抗理论探讨.福建中医学院学报,2005；15(2)：50-52
[159]马静,金季玲,补肾化痰法治疗肥胖型多囊卵巢综合征30例.山东中医杂志,2007； 26(8)：537-538
[160]何贵翔,沙玲,补肾滋阴汤对PCOS患者月经周期及性激素影响的临床观察.华西医学,2009；(7)：1-4
[161]刘广南,邝少松,潘竞锵等.益肾Ⅰ方对PCOS大鼠胰岛素抵抗及血糖、血脂的影响.中医药临床杂志,2009；21(3)：189-191
[162]王燕萍,顺慧芳,补肾化痰活血法治疗青春期多囊卵巢综合征33例临床观察.2008；15(2)：66-67
[163]邓春枝,骆黎静,刘新蕊,补肾方治疗肾阴虚型多囊卵巢综合征临床观察.2007；25(9)：1985-1986
[164]吴建辉,俞超芹,周巧玲等.补肾化瘀祛痰方治疗多囊卵巢综合征的临床研究.中国中西医结合杂志,2007；27(10)883-886
[165]许金榜,吕绍光,林元等.中医药治疗多囊卵巢综合征胰岛素抵抗30例临床观察.福建医药杂志,2007；29(5)：145-148
[166]周静,高晟,吴深涛,化浊解毒法治疗多囊卵巢综合征合并胰岛素抵抗27例.天津医药,2009；37(9)：782-783
[167]Lind AK, Weijdegard B, Dahm-Kahler P, et al. Collagens in the human ovary and their changes in the perifollicular stroma during ovulation. Acta ObstetGynecolScand.2006;85(12):1476-84
[168]RODGERS R J, IRVING—RODGERS H F, RUSSELL D L. Extracellular matrix of the developing ovarian follicle[J]. Reproduction,2003,126(4):415—424
[169]RAPTIS A E, VIBERTI G. Pathogenesis of diabetic nephropathy[J]. Exp Clin Endocrinol Diabetes,2001,109, suppl 2:S424-437
[170]龚衍,李尚为,胰岛素对卵巢颗粒细胞的作用.生殖与避孕,2008；11(28)：677-680
[171]胡敏,多囊卵巢综合征卵泡膜细胞功能的研究.生殖与避孕,2008；7(28)：444-447
[172]梁晨,李威,吴效科,女性腹型肥胖与多囊卵巢综合征.医学研究杂志,2010；39(8)：113—114
[173]施茵,虞莉青,多囊卵巢综合征与肥胖的关系及其中医治疗,针灸临床杂志,2010 年：26(2)：61—65
[174]李武呜,谢铁男,多囊卵巢综合征组织胰岛素抵抗及治疗的研究进展.吉林医学,2010：31(4)：534—535
[175]游凯,多囊卵巢综合征患者的血脂异常及其处理要点.中华妇产科杂志,2007；42(10)：716—719